Synthesis, Docking Studies and Biological Activity of New Benzimidazole- Triazolothiadiazine Derivatives As Aromatase Inhibitor

Overview

Journal Molecules

Publisher MDPI

Specialty Biology

Date 2020 Apr 8

PMID 32252458

Citations 11

Authors

Ulviye Acar Cevik

Betul Kaya Cavusoglu

Begum Nurpelin Saglik

Derya Osmaniye

Serkan Levent

Sinem Ilgin

Yusuf Ozkay

Zafer Asim Kaplancikli

Affiliations

Soon will be listed here.

Abstract

In the last step of estrogen biosynthesis, aromatase enzyme catalyzes the conversion of androgens to estrogens. Aromatase inhibition is an important way to control estrogen-related diseases and estrogen levels. In this study, sixteen of benzimidazole-triazolothiadiazine derivatives have been synthesized and studied as potent aromatase inhibitors. First, these compounds were tested for their anti-cancer properties against human breast cancer cell line (MCF-7). The most active compounds , , , and on MCF-7 cell line were subject to further in vitro aromatase enzyme inhibition assays to determine the possible mechanisms of action underlying their activity. Compound showed slight less potent aromatase inhibitory activity than that of letrozole with IC = 0.032 ± 0.042 µM, compared to IC = 0.024 ± 0.001 µM for letrozole. Furthermore, compound and reference drug letrozole were docked into human placental aromatase enzyme to predict their possible binding modes with the enzyme. Finally, ADME parameters (absorption, distribution, metabolism, and excretion) of synthesized compounds (-) were calculated by QikProp 4.8 software.

Citing Articles

Benzimidazole scaffold as a potent anticancer agent with different mechanisms of action (2016-2023).

Hagar F, Abbas S, Atef E, Abdelhamid D, Abdel-Aziz M Mol Divers. 2024; 29(2):1821-1849.

PMID: 39031290 DOI: 10.1007/s11030-024-10907-8.

Synthetic Methods and Pharmacological Potentials of Triazolothiadiazines: A Review.

Mostafa M, Radini I, El-Rahman N, Khidre R Molecules. 2024; 29(6).

PMID: 38542962 PMC: 10975507. DOI: 10.3390/molecules29061326.

Aromatase Inhibitors as a Promising Direction for the Search for New Anticancer Drugs.

Janowska S, Holota S, Lesyk R, Wujec M Molecules. 2024; 29(2).

PMID: 38257259 PMC: 10819800. DOI: 10.3390/molecules29020346.

Benzimidazole and its derivatives as cancer therapeutics: The potential role from traditional to precision medicine.

Lee Y, Tan Y, Oon C Acta Pharm Sin B. 2023; 13(2):478-497.

PMID: 36873180 PMC: 9978992. DOI: 10.1016/j.apsb.2022.09.010.

Seed-derived peptide lunasin suppressed breast cancer cell growth by regulating inflammatory mediators, aromatase, and estrogen receptors.

Hsieh C, Wu C, Peng S, Chang C Food Nutr Res. 2023; 67.

PMID: 36794014 PMC: 9899045. DOI: 10.29219/fnr.v67.8991.

References

Chamduang C, Pingaew R, Prachayasittikul V, Prachayasittikul S, Ruchirawat S, Prachayasittikul V . Novel triazole-tetrahydroisoquinoline hybrids as human aromatase inhibitors. Bioorg Chem. 2019; 93:103327. DOI: 10.1016/j.bioorg.2019.103327. View

Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H . Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science. 1995; 270(5241):1491-4. DOI: 10.1126/science.270.5241.1491. View

Song Z, Liu Y, Dai Z, Liu W, Zhao K, Zhang T . Synthesis and aromatase inhibitory evaluation of 4-N-nitrophenyl substituted amino-4H-1,2,4-triazole derivatives. Bioorg Med Chem. 2016; 24(19):4723-4730. DOI: 10.1016/j.bmc.2016.08.014. View

Hennebert O, Montes M, Favre-Reguillon A, Chermette H, Ferroud C, Morfin R . Epimerase activity of the human 11beta-hydroxysteroid dehydrogenase type 1 on 7-hydroxylated C19-steroids. J Steroid Biochem Mol Biol. 2009; 114(1-2):57-63. DOI: 10.1016/j.jsbmb.2008.12.015. View

Steele R, Mellor L, Sawyer W, Wasvary J, BROWNE L . In vitro and in vivo studies demonstrating potent and selective estrogen inhibition with the nonsteroidal aromatase inhibitor CGS 16949A. Steroids. 1987; 50(1-3):147-61. DOI: 10.1016/0039-128x(83)90068-5. View

Cepa M, Tavares da Silva E, Correia-da-Silva G, Roleira F, Teixeira N . Synthesis and biochemical studies of 17-substituted androst-3-enes and 3,4-epoxyandrostanes as aromatase inhibitors. Steroids. 2008; 73(14):1409-15. DOI: 10.1016/j.steroids.2008.07.001. View

Brueggemeier R, Hackett J, Diaz-Cruz E . Aromatase inhibitors in the treatment of breast cancer. Endocr Rev. 2005; 26(3):331-45. DOI: 10.1210/er.2004-0015. View

Augusto T, Amaral C, Varela C, Bernardo F, da Silva E, Roleira F . Effects of new C6-substituted steroidal aromatase inhibitors in hormone-sensitive breast cancer cells: Cell death mechanisms and modulation of estrogen and androgen receptors. J Steroid Biochem Mol Biol. 2019; 195:105486. DOI: 10.1016/j.jsbmb.2019.105486. View

Leechaisit R, Pingaew R, Prachayasittikul V, Worachartcheewan A, Prachayasittikul S, Ruchirawat S . Synthesis, molecular docking, and QSAR study of bis-sulfonamide derivatives as potential aromatase inhibitors. Bioorg Med Chem. 2019; 27(19):115040. DOI: 10.1016/j.bmc.2019.08.001. View

10.

Acar Cevik U, Saglik B, Osmaniye D, Levent S, Kaya Cavusoglu B, Karaduman A . Synthesis and docking study of benzimidazole-triazolothiadiazine hybrids as aromatase inhibitors. Arch Pharm (Weinheim). 2020; 353(5):e2000008. DOI: 10.1002/ardp.202000008. View

11.

Prior A, Yu X, Park E, Kondratyuk T, Lin Y, Pezzuto J . Structure-activity relationships and docking studies of synthetic 2-arylindole derivatives determined with aromatase and quinone reductase 1. Bioorg Med Chem Lett. 2017; 27(24):5393-5399. PMC: 5705205. DOI: 10.1016/j.bmcl.2017.11.010. View

12.

Bonfield K, Amato E, Bankemper T, Agard H, Steller J, Keeler J . Development of a new class of aromatase inhibitors: design, synthesis and inhibitory activity of 3-phenylchroman-4-one (isoflavanone) derivatives. Bioorg Med Chem. 2012; 20(8):2603-13. PMC: 3933949. DOI: 10.1016/j.bmc.2012.02.042. View

13.

Doiron J, Soultan A, Richard R, Toure M, Picot N, Richard R . Synthesis and structure-activity relationship of 1- and 2-substituted-1,2,3-triazole letrozole-based analogues as aromatase inhibitors. Eur J Med Chem. 2011; 46(9):4010-24. DOI: 10.1016/j.ejmech.2011.05.074. View

14.

Shoombuatong W, Schaduangrat N, Nantasenamat C . Towards understanding aromatase inhibitory activity via QSAR modeling. EXCLI J. 2018; 17:688-708. PMC: 6123608. DOI: 10.17179/excli2018-1417. View

15.

Lipinski C, Lombardo F, Dominy B, Feeney P . Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2001; 46(1-3):3-26. DOI: 10.1016/s0169-409x(00)00129-0. View

16.

Ghosh D, Griswold J, Erman M, Pangborn W . Structural basis for androgen specificity and oestrogen synthesis in human aromatase. Nature. 2009; 457(7226):219-23. PMC: 2820300. DOI: 10.1038/nature07614. View

17.

Trunet P, Vreeland F, Royce C, Chaudri H, Cooper J, Bhatnagar A . Clinical use of aromatase inhibitors in the treatment of advanced breast cancer. J Steroid Biochem Mol Biol. 1997; 61(3-6):241-5. View

18.

Jorgensen W, Duffy E . Prediction of drug solubility from structure. Adv Drug Deliv Rev. 2002; 54(3):355-66. DOI: 10.1016/s0169-409x(02)00008-x. View

19.

Asadi P, Khodarahmi G, Farrokhpour H, Hassanzadeh F, Saghaei L . Quantum mechanical/molecular mechanical and docking study of the novel analogues based on hybridization of common pharmacophores as potential anti-breast cancer agents. Res Pharm Sci. 2017; 12(3):233-240. PMC: 5465832. DOI: 10.4103/1735-5362.207204. View

20.

Rampogu S, Baek A, Bavi R, Son M, Cao G, Kumar R . Identification of Novel Scaffolds with Dual Role as Antiepileptic and Anti-Breast Cancer. IEEE/ACM Trans Comput Biol Bioinform. 2018; 16(5):1663-1674. DOI: 10.1109/TCBB.2018.2855138. View